Background: IFN-α contributes extensively to host immune response upon viral infection through antiviral, proapoptotic, antiproliferative and immunomodulatory activities. Although extensively documented in various types of human cancers and viral infections, controversy exists in the exact mechanism of action of IFN-α in human immunodeficiency virus type 1 (HIV-1) and human T-lymphotropic virus type 1 (HTLV-1) retroviral infections.
Background
The two pathogenic human retroviruses, human immunodeficiency virus type 1 (HIV-1) and human Tlymphotropic virus type 1 (HTLV-1), remain responsible for significant morbidity and mortality worldwide. At present, 33 million people are estimated to be infected with HIV-1 and 10 to 30 million people with HTLV-1 [1, 2] . Although both retroviruses share similarities in routes of transmission and in vivo tropism for CD4+ T cells, HIV-1 and HTLV-1 significantly differ in pathogenicity, disease progression and treatment outcome. Current treatment of HIV-1-infected individuals is based on highly active antiretroviral therapy (HAART), combining HIV-1 reverse transcriptase, protease, integrase and/or entry inhibitors [3] . HAART reduces HIV-1 plasma viral loads to undetectable levels in the majority of patients, hereby slowing down clinical progression to the acquired immunodeficiency syndrome (AIDS). HTLV-1, on the other hand, is able to cause adult T cell leukemia/lymphoma (ATLL), as well as HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/ TSP), albeit in a minority of infected individuals [1, 4, 5] . ATLL is an aggressive T cell malignancy of mainly CD4 + CD25+ T cells, affecting up to 6% of HTLV-1-infected individuals [5] . The diversity of patient symptoms together with their prognosis has led to the classification of ATLL into four clinical subtypes: acute, lymphoma, smouldering and chronic ATLL. Recently, consensus guidelines have been drafted for ATLL treatment with first line therapy comprising combination chemotherapy regimens for lymphoma patients and zidovudine (AZT) and interferon-α (IFN-α) combination therapy for treatment of acute, smouldering and chronic ATLL patients [6, 7] . Up to 5% of HTLV-1-infected individuals may develop HAM/TSP, a neuro-inflammatory disease characterized by demyelinating lesions and lymphocytic activation and infiltration into the central nervous system [8, 9] . Treatment of HAM/TSP patients consists of mainly symptomatic (antispasmodics) and empirical strategies such as the use of immunosuppressive drugs (corticosteroids), IFN-α or vitamin C [10] . However, consensus guidelines for HAM/TSP treatment are missing due to the lack of randomized controlled clinical trials.
Although recent genetic evidence has implicated IFN/STAT1/FAS signaling in both HAM/TSP and ATL pathogenesis [11, 12] , therapeutic options include IFN-α for both diseases. Initially, IFN-α was implemented in anti-HTLV-1 treatment because of its effect in HIV-1/ AIDS treatment [13] . IFN-α was one of the first cytokines to be discovered and contributes extensively to the host immune response upon viral infection. Type I interferons (IFN-α/β) are expressed and secreted by various cell types in response to viral infection or recognition of pathogens [14] [15] [16] . IFN-α signaling pathways are initiated by binding of IFN-α to the heterodimeric interferon-α/β receptor, consecutively activating JAK/STAT pathways. Phosphorylated STAT1 homodimers and/or the interferon-stimulated gene factor 3 (ISGF3) complex, comprising phosphorylated STAT1, phosphorylated STAT2 and interferon regulatory factor 9 (IRF9), are formed, leading to the transcriptional activation of interferon-stimulated genes (ISGs) [17, 18] . Classical well-characterized ISGs include 2' ,5'-oligoadenylate synthetase (OAS), protein kinase R (PKR), interferon regulatory factors (IRFs) and myxovirus resistance (Mx) genes [15, 17, 19] . Although the precise function of several other ISGs remains poorly understood, expression of ISGs inhibits replication of various types of viruses [19] [20] [21] [22] [23] . In addition to antiviral activity, IFN-α has profound effects on apoptosis and immune response in several types of human cancer and viral infections [16, [24] [25] [26] [27] [28] [29] [30] [31] .
HIV-1 replication can be inhibited in vitro by IFN-α in both macrophages as well as T cells, affecting both early and late stages of the viral replication cycle [20, [32] [33] [34] [35] [36] [37] [38] . Antiviral activity of IFN-α was characterized by the expression of numerous ISGs. However, the in vivo antiviral activity of IFN-α and its contribution to HIV-1 disease progression remain controversial and need to be further elucidated. Higher levels of serum IFN-α, IFN-α-induced immune activation and higher transcriptional levels of ISGs are paradoxically correlated with higher HIV-1 viral load in HIV-1-infected individuals [39] [40] [41] [42] [43] , as well as disease progression, questioning its antiviral activity in vivo. Nevertheless, clinical trials have reported modest but significant decreases in HIV-1 viral load after IFN-α treatment [13, [44] [45] [46] .
In HTLV-1-infected cells, in vitro antiviral activity has been reported for IFN-α by a post-transcriptional mechanism impairing viral assembly. Hereby, IFN-α had no effect on viral protein synthesis, but inhibited virion release through the inhibition of Gag protein association with lipid rafts [47] . In addition, IFN-α stimulation induced transcriptional activation of ISGs in HTLV-1-infected cells, reflecting intact IFN-α signaling pathways [48] . However, HTLV-1 expression has been reported to blunt IFN-α signaling pathways in vitro via HTLV-1 Tax and suppressor of cytokine signaling 1 (SOCS1) expression [48] [49] [50] . Such inhibition could impair antiviral, immunomodulatory and antiproliferative activities of IFN-α in vivo. Nevertheless, significant clinical benefit has been demonstrated for ATLL patients treated with AZT and IFN-α combination therapy and HAM/TSP patients treated with IFN-α monotherapy [7, 51, 52] . In conclusion, although IFN-α signaling pathways contribute extensively to the host immune and antiviral responses and therefore significantly determine the therapeutic success of IFN-α treatment, controversy exists in the exact mechanism of action of IFN-α in retroviral infections.
In the present study, we address the possible antiviral, antiproliferative and/or pro-apoptotic effects of IFN-α in HTLV-1 mono-infected and HIV-1/HTLV-1 co-infected CD4+ T cell lines in vitro. We demonstrate that IFN-α exerts pronounced anti-HIV-1 effects in HTLV-1 coinfected cells, but has a limited, post-transcriptional, antiviral effect upon HTLV-1 in mono-infected cells. As demonstrated by gene expression profiling, both STAT1/ STAT2-mediated antiviral signaling pathways and broad ISGs induction were fully activated by IFN-α in HTLV-1-infected cells. However, IFN-α failed to inhibit mRNA levels of any of the known HTLV-1 genes or to induce significant pro-apoptotic or antiproliferative activity in HTLV-1-infected cells. In conclusion, the apparent absence of IFN-α antiretroviral activity is selective towards HTLV-1, since a significant anti-HIV-1 effect can be observed in co-infected cells. Figure 2A ). In contrast, cell viability of and thus reflecting strong inhibition of HIV-1 p24 production and/or secretion in HIV-1/HTLV-1 co-infected MT-4 cells ( Figure 2B ). In parallel, IFN-α did not markedly affect HTLV-1 p19 levels in cell-free supernatant of HTLV-1 mono-infected MT-4 cells (ANOVA, p = 0.96), even at high doses ( Figure 2C ). In addition, HTLV-1 p19 protein levels were also determined in cell-free supernatant of the HTLV-1 positive and virion-producing MT-2 cell line. To obtain maximum biological activity, MT-2 cells were treated for 48 hours with a fixed concentration of 1000 IU/ml of IFN-α. IFN-α significantly reduced p19 levels in cell-free supernatant of MT-2 cells by 31% (n = 5, t-test, p = 0.0045, Figure 2D ), confirming the results of Feng et al. [47] . Nevertheless, IFN-α was 1,000-fold more active against HIV-1 than HTLV-1, when judged according to the inhibition of Gag protein levels (p24 for HIV-1 and p19 for HTLV-1). In HIV-1 III B /HTLV-1 co-infected MT-4 cells, 1.2 IU/ml of IFN-α inhibited 50% of HIV-1 p24 levels, whereas 1000 IU/ml of IFN-α was not even sufficient to inhibit 50% of HTLV-1 p19 levels in HTLV-1 mono-infected cells.
To evaluate the potential clinical relevance of this observation, we quantified HTLV-1 p19 levels in cell-free supernatant of HAM/TSP (n = 5) and ATLL (n = 6) PBMCs. IFN-α exerted no significant effect upon p19 levels of HAM/TSP PBMCs (t-test, p = 0.63), in agreement to our recent demonstration of a lack of ex vivo antiviral, pro-apoptotic and antiproliferative effects of IFN-α in HAM/TSP patients [54] . However, IFN-α significantly decreased p19 levels of ATLL PBMCs with 26% (t-test, p = 0.031) ( Figure 2E ). This modest reduction of p19 levels observed in ATLL PBMCs was highly similar to the IFN-α-induced reduction observed in MT-2 cells ( Figure 2D ) and to recent findings in larger cohorts of HTLV-1-infected individuals [55] as well as ATL patients (Khouri et al., unpublished).
Gene expression profiling of IFN-α-treated HTLV-1-infected cell lines
While HIV-1 replication was extremely sensitive to IFN-α antiviral activity in HIV-1/HTLV-1 co-infected MT-4 cells, anti-HTLV-1 activity remains questionable since we did not detect an effect of IFN-α on cell viability of HTLV-1 mono-infected cells. However, we could measure a modest inhibitory effect of IFN-α on HTLV-1 p19 protein levels in MT-2 cells. To clarify whether IFN-α signaling is blunted in HTLV-1-infected cell lines, possibly explaining the lack of IFN-α responsiveness, we performed gene expression profiling of MT-2 and MT-4 cells after 6 hours of IFN-α stimulation. Agilent Whole Humane Genome microarray analysis was performed in two separate microarray experiments with duplicate samples for both cell lines. Gene expression profiling of MT-2 revealed 77 genes significantly regulated by IFN-α, of which 64 were up-and 13 down-regulated. Gene expression profiling of MT-4 revealed 284 genes significantly regulated by IFN-α, of which 262 were up-and 22 down-regulated. The top 20 of the most significant upregulated genes are shown in Table 1 for MT-2 and  Table 2 for MT-4 cells, and included classical ISGs such as Mx, OAS and IRFs genes. We found no common down-regulated genes for MT-2 and MT-4, while 69% (44/64) of up-regulated genes of MT-2 were also upregulated in MT-4 cells. Altogether, gene expression profiling demonstrated significant activation of ISGs and thus intact IFN-α signaling in HTLV-1-infected MT-2 and MT-4 cells.
Pathway analysis confirms intact IFN-α antiviral signaling pathways in HTLV-1-infected cell lines
In order to characterize possible antiviral, pro-apoptotic and/or antiproliferative pathways represented by the respective IFN-α up-and down-regulated genes, which were identified via microarray analysis described above, Ingenuity Pathway Analysis (IPA) was performed for both cell lines. Genes were sorted into molecular gene networks and canonical pathways, of which significantly overrepresented networks/pathways were identified. In the case of MT-2, seven molecular networks were identified as significantly modulated by IFN-α treatment. The principal network contained 25 genes, all up-regulated, representing antimicrobial and inflammatory responses. In the case of MT-4, 12 molecular networks could be identified as significantly modulated by IFN-α treatment. The principal network contained 26 genes, all up-regulated, representing infection mechanism. The principal IFN-α-modulated canonical pathway was identical for both cell lines, i.e. interferon signaling (Figure 3 ), although subtle differences were observed (IFN-γ, MX1, up-regulated only in MT-2 and JAK2, SOCS1, IRF1, TAP1, OAS1, up-regulated only in MT-4). Thus, IPA illustrated IFN-α-induced modulation of molecular networks and pathways implicated in viral infection and/or IFN signaling in both cell lines. Moreover, no apoptotic, cell cycle-related or antiproliferative pathways were identified, corroborating our flow cytometry findings that IFN-α had no effect on cell viability of HTLV-1-infected cell lines.
Lack of antiviral activity of IFN-α in HTLV-infected cell lines
To assess the possible antiviral activity of IFN-α against HTLV-1 and to validate cellular genes identified through microarray analysis, nCounter analysis was performed [56] . All known HTLV-1 viral genes, including the antisense HBZ, and a selection of specific cellular genes, i.e. STAT1, STAT2, STAT3 and CD69, an IFN-induced early activation marker of T lymphocytes, were included for nCounter analysis. mRNA levels of selected genes were quantified and normalized to a cellular housekeeping gene (hypoxanthine phosphoribosyl-transferase 1). IFN-α significantly increased mRNA levels of STAT1 and STAT2 genes in MT-2 and MT-4 cells (n = 4, t-test, p = 0.0024, p = 0.010 and p = 0.0023, p = 0.032, respectively, Figure 4) , confirming functional activation of JAK/STAT pathways and IFN-α antiviral signaling. Moreover, mRNA levels of cellular STAT3 and CD69 genes were also significantly increased in MT-4 cells, confirming our microarray results (n = 4, t-test, p = 0.0041, p = 0.0018, respectively, data not shown). As indicated by pathway analysis ( Figure 5A-B) , IFN-α predominantly activated STAT1 and STAT2 signaling and downstream genes, representing main antiviral pathways, rather than STAT3 signaling, representing inflammatory and carcinogenic pathways. HTLV-1 viral mRNA levels were ± 10-fold higher in MT-2 cells, in comparison to MT-4 cells, in agreement with the superior virion production by MT-2 cells (Figure 2C-D) . Surprisingly, after 6 hours, IFN-α treatment had no effect on mRNA levels of any of the HTLV-1 viral genes in both cell lines (n = 4, t-test, Figure 6A -B). Due to the surprising absence of an antiviral effect at 6 hours, we also performed nCounter analysis after 2 and 48 hours of IFN-α treatment of MT-2 and MT-4 cells to verify whether "early" or "late" inhibition of HTLV-1 viral gene transcription might occur. At 2 hours, IFN-α again had no effect on viral gene mRNA levels in both cell lines (n = Because of the intact transcriptional activation of ISGs, the absence of distinct antiviral activity of IFN-α against HTLV-1 was not due to a general defect in IFN-α signaling pathways in MT-2 or MT-4 cells. In agreement with our findings, over-expression of a subset of ISGs in chronic HTLV-1 infection has recently been shown to fail to constitute an efficient antiviral host response, but might instead contribute to HAM/TSP pathogenesis [55] . We speculate that IFN-α fails to decrease HTLV-1 mRNA levels due to highly virus-specific retroviral restriction factors, as IFN-α exerted strong anti-HIV-1 yet weak anti-HTLV-1 effects in HIV-1/HTLV-1 co-infected MT-4 cells. Since all known HTLV-1 mRNAs, including antisense HBZ, remain unchanged upon IFN treatment, defective RNAseL activity, downstream of OAS gene activation (reviewed in [57] ), might be hypothesized as a possible HTLV-1 escape mechanism,. Although several OAS family members are IFN-inducible in both HTLV-1 infection (this study, Table I and results not shown) and HIV-1 infection [40] , little is known of downstream RNAse L activation, which occurs at the protein level [57] . In addition, blunting of IFN-α biological activity has been mainly addressed in HTLV-1 mono-infection, but not in HIV-1/HTLV-1 coinfection. HTLV-1 expression has been reported to up-regulate SOCS1 expression, inducing ubiquitination and proteasomal degradation of IRF3, leading to the inhibition of type I interferon production and thus inhibiting activation of IFN-α signaling pathways [50] . Still, up-regulation of SOCS1 mRNA levels was shown in CD4+ T cells isolated from HAM/TSP patients and asymptomatic carriers, but not from ATLL patients [50] . Furthermore, HTLV-1 Tax has been shown to induce SOCS1 expression, leading to the inhibition of RIG-I-dependent antiviral signaling, but not the JAK/STAT signaling pathways [58] . Inhibition of cytoplasmatic pattern recognition receptors such as RIG-I, has been associated with IRF3 inhibition and thus subsequent inhibition of type I interferon production. Consequently, HTLV-1-induced SOCS1 expression could counteract activation of IFN-α signaling via reduced type I interferon production. However, Figure 4 Quantification of STAT1 and STAT2 mRNA levels of HTLV-1-infected cell lines. HTLV-1-infected CD4+ T cell lines (A) MT-2 and (B) MT-4 were treated for 6 hours with no treatment (NT) or IFN-α (1000 IU/ml). mRNA levels (fM) of cellular STAT1 and STAT2 genes were assessed via nCounter analysis and shown in the y-axis, whereas the treatment conditions are shown in the x-axis. Parametric t-tests were used with p-values indicated by asterisks ( * < 0.05, ** < 0.01 and *** < 0.001). whereas exogenous IFN-α has been shown to increase SOCS1 expression in HeLa-cells, HTLV-1 expressed from an infectious molecular clone reduced IFN-α-induced up-regulation of SOCS1 mRNA levels [48] . Taken together, the precise correlation between HTLV-1 and SOCS1 expression and its effect on IFN-α signaling, remains unclear. Our microarray analysis revealed significant IFN-α-induced up-regulation of suppressors of cytokine signaling SOCS1, SOCS2 and SOCS3 levels in MT-4 cells, but not in MT-2 cells, although IPA pathway analysis revealed strikingly similar IFN signaling in both cell lines. Therefore, an IFN-α-induced increased SOCS1 level is not a generalized finding in HTLV-1 infection in vitro and is not by itself sufficient to define the blunted biological activity of IFN-α. HTLV-1 expression has also been reported to upregulate IRF4 levels in HTLV-1-transformed cell lines and PBMCs of ATLL patients [59, 60] . IRF4 was shown to negatively regulate type I interferon production and appeared to be associated with AZT + IFN-α antiviral resistance in ATLL patients [59] [60] [61] . Our microarray results showed no effect of IFN-α on IRF4 expression in MT-2 or MT-4 cells, although more sensitive nCounter analysis revealed slight IFN-α-induced upregulation of IFR4 levels, which was significant in MT-4 cells, but not in MT-2 cells (p = 0.049 and p = 0.65, respectively, data not shown). Furthermore, treatment with exogenous IFN-α was able to activate IFN-α signalling to a similar extent in both cell lines (Figure 6A-B and Tables 1-2) , although SOCS1 and IRF4 were significantly up-regulated in MT-4 cells only. Nevertheless, our study was limited to the broad antiviral, pro-apoptotic and antiproliferative activities of IFN-α, as well as IFN-α signaling in HTLV-1-infected cells, whereas the precise contribution of cellular factors such as SOCS1 or IRF4 has been investigated in detail in previous studies [50, [58] [59] [60] [61] . However, it should be stated that some of these studies [48, 50] investigate de novo infection with HTLV-1 molecular clones, in contrast to stable HTLV-1 infection (this study). The latter might be closer to the in vivo situation, considering the latency of the virus in vivo and its slow molecular evolution, pointing at limited de novo infection [1] . In addition, there is increasing evidence that activation of multiple IFN-α signaling pathways is required to generate the antiviral, pro-apoptotic and immunomodulatory effects of IFN-α [16] . Antiviral and antiproliferative activities of IFN-α have been reported to depend on both STAT-and p38-signaling pathways [62] . Although we observed transcriptional activation of STAT1, STAT2 and downstream ISGs in both MT-2 and MT-4 cells, other important IFN-α signaling pathways, such as p38-signaling, could be affected by HTLV-1 replication, possibly explaining the absence of explicit antiviral or antiproliferative activity against HTLV-1 in vitro. Altogether, one can assume that the in vitro antiretroviral activity and, possibly, the in vivo therapeutic success of IFN-α for both HIV-1 and HTLV-1 is determined by virus-specific factors including viral life cycle-related factors (replication, virion production) and the balance between factors blunting or stimulating IFN-α signaling pathways. For example, inhibition of HIV-1 assembly and release of virions by IFN-α has been described through the induction of ISG15, an ubiquitin-like protein [34] . Through ISG15 up-regulation, IFN-α could affect HTLV-1 assembly, which could explain the posttranscriptional inhibition of p19 secretion. On the other hand, a recent systematic screen for antiviral activity of 389 ISGs, revealed the ability of ADAR to enhance HIV-1 replication [31] . Unfortunately, no data are available on IFN signaling and/or specific ISGs levels in HIV-1/ HTLV-1 co-infection, which is of significant clinical importance since several cohort studies have revealed accelerated clinical progression to AIDS and/or increased mortality in HIV-1/HTLV-1 co-infected versus HIV-1 mono-infected individuals [63] [64] [65] .
Conclusion
We found that IFN-α treatment of retrovirus-infected CD4+ T cells revealed strong anti-HIV-1 but limited anti-HTLV-1 effects. We demonstrate intact early as well as sustained IFN-α signaling in HTLV-1-infected cells, despite various reports of SOCS1-and HTLV-1 Taxinduced blunting of IFN-α signaling. We speculate that qualitative rather than quantitative differences in IFN-α signaling and downstream ISGs could determine the therapeutic success of IFN-α in vivo, depending on both host genetics and disease context. Therefore, large cohorts with long-term clinical follow-up of ATLL and HAM/TSP patients, as well as HIV-1/HTLV-1 coinfected individuals are required to identify viral and host factors specifically limiting antiretroviral activity of IFN-α against HTLV-1. 
Materials and methods
Reagents IFN-α2A (3x10 6 IU/ml, a gift of Blausiegel Farmacêutica, São Paulo, Brazil) stock solutions were prepared in normal saline and working solutions in RPMI 1640 medium, supplemented with 10% heat inactivated foetal calf serum, 20 μg/ml gentamicin and 75 mM NaHCO 3 (GIBCO W Invitrogen, Belgium). Antiviral activity of IFN-α was confirmed in a Vesicular Stomatitis Virus/WISH bioassay [66] .
Patients samples and cell lines
Diagnosis of HTLV-1 infection, HAM/TSP and ATLL was made according to published criteria [67] , combining ELISA (Murex), Western blot, INNO-LIA (Innogenetics) and clinical data. Written informed consent was obtained from all participants and this study was approved by the Ethics Committees of CpqGM-FIOCRUZ and HUPES/UFBA (Salvador-Bahia, Brazil) and the Universidad Peruana Cayetano Heredia (Lima, Peru). PBMCs of 5 HAM/TSP and 6 ATLL patients (4 acute, 2 chronic) were isolated by Ficoll-Hypaque density gradient centrifugation (Sigma-Aldrich).
PBMCs and chronically HTLV-1-infected cell lines, C8166, MT-2 and MT-4 [68] [69] [70] , were cultured in supplemented RPMI 1640 medium. C8166 cells were obtained from the Medical Research Council, UK), MT-2 and MT-4 cells were from Harada et al. [71] . For varying time spans, PBMCs (2 x 10 6 cells/ml) and HTLV-1-infected cell lines (2 x 10 5 cells/ml) were treated in the absence or presence of IFN-α (10 -10 4 IU/ml) followed by flow cytometric analysis of HTLV-1-infected cell lines. Given that MT-4 cells are highly susceptible to HIV-1 infection and have been successfully used as a drug screening model for the detection of anti-HIV compounds [53] , MT-4 cells (6 x 10 5 cells/ml) were infected with HIV-1 III B strain [72] and cultured for 5 days in the absence or presence of varying concentrations of IFN-α (0.01 -10 4 IU/ml). Hereby, antiviral activity of IFN-α was measured via the 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) cell viability staining assay [53, 73] . In parallel, HTLV-1-mono-infected MT-4 cells (6 x 10 5 cells/ml) were cultured for 5 days in the absence or presence of varying concentrations of IFN-α (10 -10 4 IU/ml). Cell viability was quantified by both MTT assay and trypan blue dye exclusion protocols.
Flow cytometry assay
At different time points after IFN-α treatment, cell lines were collected and DNA content (Hoechst 33342), cell death-associated (active-caspase-3, surface Fas) and cell proliferation-associated (PCNA) markers were quantified by flow cytometry (BD Biosciences). Briefly, cells were fixed in Cytofix buffer (BD Biosciences) for 10 minutes at 37°C. Cell pellets were permeabilized in 100% ice-cold methanol for 30 minutes. Cells were then washed twice in 1x PBA (phosphatebuffered saline + bovine serum albumin + NaN 3 ) and incubated with fluorescence-labelled monoclonal antibodies at room temperature (APC mouse IgG1, FITC mouse IgG2a, PE mouse IgG2a, APC anti-Fas, FITC anti-PCNA, PE anti-active Caspase-3). After 30 minutes, cells were washed twice in 1 x PBA and stained with Hoechst 33342. Cell populations and debris were defined based on morphology via forward-versus side-scatter plots and 10.000-100.000 events were acquired per sample.
HIV-1 p24 and HTLV-1 p19 quantification HIV-1 capsid protein p24 and HTLV-1 matrix protein p19 were quantified in cell-free supernatant of MT-4 and MT-2 cells, using HIV-1 p24 Core Profile ELISA kit (PerkinElmer) and RetroTek HTLV-I/II p19 Antigen ELISA kit (ZeptoMetrix), respectively. After 48-72 hours of IFN-α treatment (1000 IU/ml), HTLV-1 p19 levels were quantified in cell-free supernatant of HAM/TSP and ATLL PBMCs.
Microarray analysis
Total RNA was extracted from MT-2 and MT-4 cells treated in the absence or presence of IFN-α (1000 IU/ ml) at 6 hours, using RNeasy kit according to the manufacturer's protocol (QIAgen Benelux B.V., Venlo, the Netherlands). Agilent Whole Human Genome microarray analysis was performed by the VIB MicroArray Facility (Leuven, Belgium). Data were analysed using the Agilent Feature Extraction Software version 10.1.1.1 and 10.5.1.1. Briefly, the intensities of the fluorescent probes Cy3 and Cy5, representing the transcription values, were log 2 -transformed and normalized by quantile normalization using the R package preprocessCore [74] . The contrasts in expression between IFN-α-treated and untreated cells at 6 hours of stimulation were estimated using the Limma package from Bioconductor (www. bioconductor.org). For the selection of differentially transcribed genes, a fold-change cut-off of two (i.e. an absolute log 2 -ratio larger than 1) was combined with a p-value cut-off of p < 0.05 when corrected for multiple testing. GEO submission of microarray data is detailed in Additional file 2.
Ingenuity pathway analysis
The Ingenuity Pathway Analysis (IPA) program was used to perform a pathway/function level analysis on genes resulting from the microarray analysis for both MT-2 and MT-4 (IPA version 9.0, Build 116623, Content version 3211, Ingenuity Systems, Red Wood City, CA). Hereby, uncorrected p-values and absolute fold-changes were used with cut-offs of p < 0.001 and fold-change value of 2 (up or down), respectively. Based on a scientific literature database, genes were sorted into gene networks and canonical pathways and significantly overrepresented pathways were identified. The maximum number of networks to be generated was set to 25, with a maximum number of 35 molecules per network. The signaling pathways and networks in Figure 3 were generated through the use of IPA (Ingenuity Systems, www.ingenuity.com).
nCounter analysis
Total RNA was extracted from MT-2 and MT-4 treated in the absence and presence of IFN-α (1000 IU/ml) at 2, 6 and 48 hours, using RNeasy kit according to the manufacturer's protocol (QIAgen Benelux B.V., Venlo, the Netherlands). nCounter TM (NanoString Technologies, Seattle, United States) analysis was performed at the VIB MicroArray Facility (Leuven, Belgium), based on direct molecular bar-coding of target RNA transcripts and digital detection [56] . Through the use of colour-coded probe pairs, without the use of reverse transcriptase nor amplification, mRNA transcripts of HTLV-1 viral genes and specific cellular genes, including housekeeping genes for normalization, were quantified in MT-2 and MT-4 cells after 2, 6 and 48 hours of IFN-α treatment (HTLV-1 Tax/Rex, Gag, protease, polymerase, gp46, gp21, NC_001436.1; HTLV-1 p13, p12, p30, AB513134; HTLV-1 HBZ, DQ273132; STAT1, NM_007315.2; STAT2, NM_005419.2; STAT3, NM_139276.2; CD69, NM_001781.1).
Statistical analysis
Statistical analysis was performed with GraphPad Prism 5 software. Parametric t-tests were used and p < 0.05 was considered significant.
In microarray analysis, a moderated t-test was used, as implemented in the Limma package, to test whether a contrast was significantly different from zero. To verify the false discovery rate, p-values were corrected for multiple testing with Benjamini-Hochberg.
